References
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive–compulsive disorder. Mol Psychiatry 11:622–632
Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49–51
da Rocha FF, Correa H (2007) Successful augmentation with aripiprazole in clomipramine-refractory obsessive–compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31(7):1550–1551
Denys D, Zohar J, Westenberg HG (2004) The role of dopamine in obsessive–compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65(Suppl 14):11–17
Dryden-Edwards RC, Reiss AL (1996) Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol 6(2):139–145
Math SB, Janardhan Reddy YC (2007) Issues in the pharmacological treatment of obsessive–compulsive disorder. Int J Clin Pract 61(7):1188–1197
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive–compulsive disorder. Arch Gen Psychiatry 57(8):794–801
Rugino TA, Janvier YM (2005) Aripiprazole in children and adolescents: clinical experience. J Child Neurol 20(7):603–610
Swainston Harrison T, Perry CM (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15):1715–1736
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarkar, R., Klein, J. & Krüger, S. Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder. Psychopharmacology 197, 687–688 (2008). https://doi.org/10.1007/s00213-008-1091-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-008-1091-1